The Myc oncoprotein forms a binary activating complex with its partner protein, Max, and a ternary repressive complex that, in addition to Max, contains the zinc finger protein Miz1. Here we show that the E3 ubiquitin ligase HectH9 ubiquitinates Myc in vivo and in vitro, forming a lysine 63-linked polyubiquitin chain. Miz1 inhibits this ubiquitination. HectH9-mediated ubiquitination of Myc is required for transactivation of multiple target genes, recruitment of the coactivator p300, and induction of cell proliferation by Myc. HectH9 is overexpressed in multiple human tumors and is essential for proliferation of a subset of tumor cells. Our results suggest that site-specific ubiquitination regulates the switch between an activating and a repressive state of the Myc protein, and they suggest a strategy to interfere with Myc function in vivo.
Introduction
The proto-oncogene c-myc encodes a transcription factor (Myc) that can both activate and repress tran-*Correspondence: kristian.helin@bric.dk (K.H.); eilers@imt.unimarburg.de (M.E.) 6 These authors contributed equally to this work. 7 Present address: Klinikum der Philipps Universität Marburg, Klinik für Hämatologie, Onkologie, und Immunologie, Marburg, Germany. scription (Eisenman, 2001 ). Myc activates transcription as part of a binary complex with its partner protein, Max. The complex binds to specific DNA sequences, termed E boxes, and stimulates transcription of a large group of genes (Adhikary and Eilers, 2005) . Myc represses transcription through the formation of a ternary complex that contains Max and the zinc-finger transcription factor Miz1. Free Miz1 binds to the core promoter of multiple Myc-repressed genes and activates these genes. Myc is recruited to these sites through interaction with Miz1 and represses transcription when tethered to Miz1.
Myc is a short-lived protein that is degraded through the ubiquitin-proteasome pathway (Salghetti et al., 1999) . Two F box E3 ligases ubiquitinate Myc and contribute to Myc degradation: Fbw7 recognizes Myc that is phosphorylated at threonine 58 by glycogen synthase kinase 3 (Gsk3) (Welcker et Ubiquitination of transcription factors can control their activity independently of proteasomal degradation. For example, Met4, a bZIP factor that regulates a large number of genes predominantly involved in methionine biosynthesis, is ubiquitinated but not degraded in the presence of high intracellular levels of S-adenosylmethionine (Kaiser et al., 2000) . Ubiquitination inactivates Met4 at least in part because it precludes recruitment of the coactivator, Cbf1 (Kaiser et al., 2000) ; in addition, binding of Met4 to a subclass of its target promoters is compromised by ubiquitination (Kuras et al., 2002) . Ubiquitination does not necessarily inhibit transcription factors since ubiquitination of the HIVTat protein by Mdm2 augments its ability to activate transcription (Bres et al., 2003) . Similarly, ubiquitination of Myc by Skp2 contributes to transcriptional activation, potentially by allowing Myc to recruit proteasomal subunits that have a proteolysis-independent role in transcriptional activation (Ferdous et al., 2001) . Two signals are known to determine whether ubiquitination leads to degradation. Proteolytic substrates are modified by polyubiquitin chains, and a minimum chain length of about four ubiquitin residues appears to be required to target the attached protein to the proteasome (Flick et al., 2004) . The lysine residue of ubiquitin, used for polyubiquitin chain formation, specifies the second signal. Whereas chains linked through lysine 48 usually lead to proteasomal degradation, those linked through lysine-63 of ubiquitin do not target proteins to the proteasome (Bres et al., 2003) .
Here we describe a Hect-domain (homologous to E6-AP carboxy-terminus; Huibregtse et al., 1995) ubiquitin ligase, which ubiquitinates Myc in a carboxy-terminal domain required for recruitment of the coactivator, p300. Our data support the hypothesis that the switch between transcriptional activation and repression by Myc is regulated by site-specific ubiquitination. HectH9 is overexpressed in multiple human tumors and is required for the proliferation of a subset of human tumor cells, closely paralleling the requirement for Myc among different cell lines. Our data suggest that interference with HectH9 provides a potential strategy to inhibit Myc function in human tumors.
Results

HectH9 Binds to Myc and Miz1 In Vivo
Miz1 is a zinc-finger transcription factor containing an amino-terminal POZ domain, which is a protein/protein interaction domain present in many zinc-finger proteins (Bardwell and Treisman, 1994) . The POZ domain of Miz1 is required for transcriptional activation of the p15ink4b and p21cip1 promoters and for suppression of cell proliferation (Herold et al., 2002).
To better understand the function of the Miz1 POZ domain, we performed a two-hybrid screen to identify novel interaction partners of Miz1. In this screen, we obtained multiple overlapping clones from a single gene, encoding a protein alternatively named HectH9, Lasu1, or KIAA0312 ( Figure 1A ). HectH9 belongs to the Hect-domain family of ubiquitin ligases ("homologous to E6AP carboxyl terminus"), which are characterized by a conserved carboxy-terminal catalytic domain (Huibregtse et al., 1995). A protein corresponding to the carboxyl terminus of HectH9 has also been described as a DNA binding protein (Ureb1; Upstream-element binding protein 1; Gu et al., 1994); however, we have been unable to confirm a significant DNA binding activity of HectH9 (R.B., unpublished data). A human cDNA encoding a protein of 4374 amino acids was assembled from several EST clones. RT-PCR using primers against four different regions of the predicted cDNA confirmed that these sequences are indeed part of the same gene ( Figure S1 ). To determine whether this cDNA encodes the full-length HectH9 protein, we transfected U2OS cells with a CMV-driven expression vector encoding an HA-tagged HectH9 protein ( Figure 1B) . Immunoblotting using antibodies directed against the HA-tag detected a protein of approximately 500 kDa in transfected cells. Both a polyclonal and different monoclonal antibodies raised against different regions of HectH9 detected an endogenous protein of 500 kDa in lysates of multiple human cell lines, which comigrated with the protein expressed from the cloned cDNA ( Figure 1B ). Based on these data, we conclude that we have isolated the fulllength open reading frame of HectH9.
To test whether HectH9 binds to Miz1 in vitro, Miz1 and an amino-terminally truncated allele of HectH9 (⌬NHectH9, see below) were synthesized by coupled transcription-translation in a reticulocyte lysate in the presence of 35 S-methionine ( Figure 1C Figure 1D ). No specific binding of Miz1⌬POZ to ⌬NHectH9 could be detected in vivo, consistent with the in vitro and twohybrid data (not shown). When ⌬NHectH9 and Myc were coexpressed, HectH9 immunoprecipitates contained significant amounts of Myc ( Figure 1E ). Myc was not recovered in control immunoprecipitates or in HectH9 immunoprecipitates from cells that did not express ⌬NHectH9, demonstrating that Myc binds to ⌬NHectH9 in vivo. Since no stable binding of Myc to ⌬NHectH9 was detected in vitro, it is likely that additional proteins stabilize binding of Myc to ⌬NHectH9 in vivo. We wondered whether endogenous HectH9 interacts with Miz1 and Myc and immunoprecipitated HeLa cell lysates with either α-HectH9 or control antibodies. Both Myc and Miz1 were coprecipitated with α-HectH9 antibodies but were absent from control immunoprecipitations ( Figure 1F ). Based on these results, we conclude that HectH9 interacts with both endogenous Miz1 and Myc in vivo. To test whether all three proteins form a ternary complex, we transfected cells with constant amounts of Myc and ⌬NHectH9 and increasing amounts of Miz1 ( Figure 1G ). In these experiments, the amount of Myc recovered in HectH9 immunoprecipitates decreased with increasing amounts of Miz1, strongly suggesting that Myc and Miz1 compete for binding to HectH9.
HectH9 Catalyzes K-63-Mediated Ubiquitination of Myc
To test whether HectH9 ubiquitinates either Miz1 or Myc, we transfected cells with expression plasmids encoding Myc, Miz1, ⌬NHectH9, and a histidine-tagged ubiquitin. Transfected cells were lysed and ubiquitinated proteins were isolated by binding to Ni-agarose. Immunoblots of the eluates were probed with antibodies directed against Miz1 and Myc (Figure 2A and data not shown). In these experiments, we did not detect any activity of ⌬NHectH9 toward Miz1 (data not shown). In contrast, ⌬NHectH9 efficiently ubiquitinated Myc. Ubiquitinated forms of Myc accumulated up to a molecular weight of 250 kDa, demonstrating that ⌬NHectH9 can We noted that GST-HectH9 polyubiquitinated itself in vitro ( Figure 2C ). Mass spectrometry revealed that the ubiquitin moieties in these chains were linked through K48, K11, and K63 to each other, demonstrating that HectH9 is capable of assembling different types of polyubiquitin chains ( Figure 2D ). In vitro reactions showed that a point mutant of ubiquitin, in which K48 is replaced by arginine (UbiK48R), was efficiently ligated to Myc; conversely, a mutant that retained K48 but replaced all other lysines by arginine was not ligated to Myc (data not shown). In vivo, UbiK48R was ligated to Myc as efficiently as wild-type ubiquitin (Figure S2) . In order to determine the type of polyubiquitin chain that HectH9 transfers to Myc in vivo, we performed ubiquitination assays using specific point mutants of his-tagged ubiquitin, in which either K11, K48, or K63 is replaced by arginine (UbiK11R, UbiK48R, and UbiK63R) ( Figure 2F ). Both UbiK11R and UbiK48R were ligated to Myc HectH9 as efficiently as wt ubiquitin; in Figure 3) . To do this, we measured in parallel binding to ⌬NHectH9 and ubiquitination by ⌬NHectH9 of a series of both N-terminal and C-terminal deletion mutants of Myc ( Figures 3A and S3 ). In these experiments, full-length Myc bound efficiently to ⌬NHectH9 and was efficiently ubiquitinated by ⌬NHectH9, as described above ( Figure 3A) . Increasingly larger deletions from the amino terminus led to a progressive loss of both binding and ubiquitination, suggesting that the amino terminus of Myc is required for binding to ⌬NHectH9 in vivo and that the loss of ubiquitination of amino-terminally deleted mutants of Myc by ⌬NHectH9 is an indirect consequence of the reduction in binding of such proteins. In contrast, the analysis of two carboxy-terminal deletions (⌬C1Myc and ⌬C2Myc) identified a region that was required for ubiquitination by ⌬NHectH9 but not for binding, suggesting that it might contain the target lysines for ⌬NHectH9. We therefore replaced the six lysines in this region by arginine in full-length Myc, generating MycKR 6 , and repeated the ubiquitination assays using wtMyc and MycKR 6 in parallel. Ubiquitination of MycKR 6 by ⌬NHectH9 was significantly reduced relative to wtMyc (Figures 3B and 3C ). We conclude that HectH9 ubiquitinates Myc at least in part on one or more of the six lysine residues that are replaced by arginine in MycKR 6 .
Immunofluorescence of transfected cells revealed that both wtMyc and MycKR 6 localized to the cell nucleus, suggesting that ubiquitination does not affect nuclear localization of Myc ( Figure 3D ). To test whether ubiquitination of Myc at these sites regulates Myc stability, we infected NIH3T3 cells with recombinant retroviruses that express wtMyc or MycKR 6 . Pools of infected cells were treated with cycloheximide for different lengths of time (Figures 3E and 3F) . Cell lysates were prepared and immunoblots were probed with the monoclonal antibody 9E10, which specifically recog- nizes human Myc. In these experiments, we observed that the rate of degradation of wtMyc and MycKR 6 was identical ( Figures 3E and 3F) . To determine how ubiquitination affects Myc function, we initially performed transient reporter assays using an E box-dependent reporter plasmid derived from the prothymosin-α (PTMA) gene, a target for activation by Myc, and a reporter plasmid carrying the core P15INK4B promoter, a target for Miz1-dependent repression by Myc ( Figure 4A ). In these transient assays, we observed no difference between wtMyc and MycKR 6 in their ability to either activate or repress transcription. Thus, mutation of the six lysines to arginines in MycKR 6 does not lead to complete loss of function.
To determine whether MycKR 6 is affected in regulating Myc target genes, we performed a gene expression analysis of pools of mouse NIH3T3 fibroblasts infected with retroviruses expressing either wtMyc or MycKR 6 . Immunoblots confirmed that the two cell pools expressed similar levels of Myc protein ( Figure 3E ). Cells were serum-starved for 48 hr to deplete endogenous Myc, and RNA was subsequently extracted and used to perform for gene-expression analysis ( Figure 4B) . Analysis of the entire dataset revealed no significant differences in the overall expression of all genes on the array (data not shown). In contrast, analysis of the genes that were induced by wtMyc relative to control cells showed that MycKR 6 activated the majority of these genes less efficiently than wtMyc (Figures 4B and  S4) . Analysis of the public database of Myc target genes revealed that this group of genes contained multiple known target genes of Myc ( Figure S4 ). Functional annotation revealed that genes encoding proteins involved in cell proliferation, in cellular metabolism, and in protein synthesis were expressed at significantly lower levels in cells expressing MycKR 6 than in cells expressing wtMyc (Figures 4B and S4) . Real-time PCR analysis confirmed that MycKR 6 activated some target genes to the same extent as wtMyc (see rbb2) but did not activate another subset of target genes that are activated by wtMyc (shown for ccna2 und ccnb1 in Figure  4C ). Taken together, the data show that MycKR 6 is deficient in activation of a significant subset of Myc target genes in vivo. Consistent with these differences in transcriptional regulation, MycKR 6 was significantly less effective in promoting proliferation of serum-starved NIH3T3 cells ( Figure 4D) .
We speculated that the failure of MycKR 6 to activate endogenous target genes despite its ability to activate transient reporter plasmids reflected the failure to recruit a coactivator. Several potential coactivators of Myc have been described, most of which bind to the amino terminus of Myc, not immediately adjacent to the target lysines for HectH9 ( Figure 5A ). In contrast, the p300 and CBP histone acetyltransferases bind to the carboxyl terminus of Myc, and we therefore speculated that ubiquitination of Myc might be required for efficient recruitment of p300 (Vervoorts et al., 2003) . To test this hypothesis, we cotransfected cells with HA-tagged p300 and either wtMyc or MycKR 6 , either by itself or in the presence of HectH9. Lysates were immunoprecipitated with antibodies against the HA-tag of p300, and the precipitates probed with antibodies directed against Myc ( Figure 5B ). In these experiments, efficient complex formation between wtMyc and p300 was observed in the presence of HectH9 but not in its absence. The efficiency of complex formation was reduced for MycKR 6 , suggesting that the lysine residues need to be ubiquitinated for complex formation to occur.
To demonstrate that MycKR 6 is deficient in recruitment of p300, we performed chromatin immunoprecipitation from cells expressing either MycER or MycKR 6 ER using primers that measure occupancy at the E box localized in the nucleolin promoter, a target of E box-dependent activation by Myc ( Figure 5C ). Upon addition of 4-OHT, both MycER and MycKR 6 ER effi-ciently bound to the nucleolin promoter. In contrast, p300 was recruited by MycER but not by MycKR 6 ER. The data suggest that MycKR 6 is deficient in transactivation of a subset of target genes because binding of Myc to p300 requires ubiquitination at one or more of the six lysines targeted by HectH9.
Miz1 inhibits ubiquitination of Myc by HectH9 ( Figure  2A) . If recruitment of p300 by Myc depends on ubiquitination by HectH9, then Myc should recruit p300 selectively to E box elements but not to Miz1 sites. We tested this model using a cell line that carries a tetracycline-inducible Myc (Schuhmacher et al., 2001 ). Chromatinimmunoprecipitations were performed before and after induction of Myc. As targets, we chose nucleolin and c/EBPa, a Miz1-dependent target of repression by Myc, since initial experiments had shown that the amounts of Myc bound to both loci are comparable to each other and higher than for all other genes tested ( Figure 5D ). Addition of tetracycline led to a similar increase of Myc binding at both loci. Induction of Myc led to enhanced binding of the histone acetyl transferase Tip60, which is recruited to MycboxII domain as part of the TRRAP complex, at both loci (Figures 5D and 5E;  Frank et al., 2003) . Similarly, enhanced binding of Tip49, which also interacts with MycboxII, was seen at both the nucleolin and c/EBPa promoters, although the effects were not as strong (Wood et al., 2000) . The data suggest that cofactors, which interact with MycboxII, are recruited to both E box targets and Miz1 binding sites in vivo. In contrast and consistent with our model, p300 is recruited to the nucleolin promoter but not to the c/EBPa promoter upon expression of Myc.
HectH9 Is Required for Myc Function In Vivo
The phenotypes of the MycKR 6 mutant might reflect the requirement for ubiquitination by HectH9 or, alternatively, reflect a HectH9-independent requirement for lysine residues at these sites. We therefore used shRNA vectors and siRNA to deplete HectH9 to provide independent evidence that HectH9 is required for Myc function in vivo.
We infected U2OS cells that express a MycER protein with either control retroviruses or retroviruses that direct the synthesis of shRNA molecules targeting HectH9. We designed three different shRNAs to HectH9; immunoblotting revealed that each of these viruses reduced the amount of endogenous HectH9 protein relative to control cells but did not affect expression of the MycER protein ( Figure 6A) . Two experiments were performed to assess how depletion of HectH9 affects Myc function: First, we activated MycER by addition of 4-OHT in serum-starved cells and isolated RNA either before or 24 hr after activation; we then performed a microarray experiment comparing gene induction by Myc in control to HectH9-depleted cells (Figures 6B  and S5 ). Depletion of HectH9 by either of the shRNAs reduced the transactivation of many but not all target genes of Myc, consistent with the phenotype of the KR 6 mutant. While the genes that were most strongly induced by Myc in U2OS cells differed from those that were most strongly induced in NIH3T3 fibroblasts, the genes that were induced in U2OS cells again contained several known target genes of Myc, suggesting that depletion of HectH9 affected transcriptional activation of Myc; in addition, comparison of the array experiments revealed a significant number of genes that were affected both by KR 6 mutation and by depletion of HectH9, arguing that both affect Myc-dependent transactivation in a similar manner (Figures S6 and S7) 
HectH9 Is Overexpressed in a Large Number of Primary Tumors
Deregulation of Myc expression contributes to the genesis of a large number of human tumors. We speculated, therefore, that the expression of HECTH9 might similarly be enhanced in human tumors. To test this, we performed tissue microarray experiments using multiple samples from primary colon patients of different stages ( Figure 7A ). In these experiments, expression of HECTH9 closely correlated with tumor stage; while it was undetectable or expressed at very low levels in normal epithelium and in polyps, moderate or high ex- pression of HECTH9 was detected in 9/27 adenomas and in 42/85 adenocarcinomas. Microscopic inspection of the colon samples confirmed that HECTH9 expression was confined to the tumor tissue ( Figure 7B) . Similarly, moderate or high expression of HECTH9 was detectable in a high percentage of lung and breast carcinomas, while it was undetectable in normal breast ( Figure 7C and data not shown) . Most likely, this is due to deregulation of HectH9 expression and not due to gene amplification, since in parallel FISH analysis we did not detect any evidence for amplification of the HECTH9 locus (data not shown). Our in situ hybridization data are supported by inspection of available expression databases, which showed that HECTH9 is higher in multiple solid tumors, including lung carcinoma, breast carcinoma, prostate carcinoma, glioblastoma, and colon carcinoma, relative to normal tissue (not shown).
To ascertain the relevance of HectH9 to tumor cell growth and proliferation, we measured expression of HECTH9 in human tumor cell lines; enhanced expression of HECTH9 relative to MRC5 diploid human fibroblasts was observed in multiple tumor cell lines ( Figure  7D ). We then used two different siRNA oligonucleotides ( Figure 7E 
Plasmid Constructs and Mutants
To identify the full-length sequence of HECTH9, we first assembled a putatively complete coding sequence using data of human ESTs and human genomic sequences available at the NCBI's Web site. The truncation mutants used for the mapping of target lysines of c-Myc have been described (Salghetti et al., 1999) . Mutants of ubiquitin and Myc were constructed using PCR-based in vitro mutagenesis; to generate MycKR 6 , lysines converting K298, K317, K323, K326, K341, and K355 were converted into arginines. 
Ubiquitination Assays
Tissue Microarrays
We prepared two multitumor tissue microarrays (TMAs; Kononen et al., 1998) and a colon progression TMA including normal epithelia, hyperplastic polyps, adenomas, and adenocarcinomas. In the colon progression TMA, we deposited, whenever possible, matched samples from the same patient. The ISH was performed as previously described (Rugarli et al., 1993) . Levels of HECTH9 expression in the in situ analysis were evaluated using a scale of 0-3, where 0 = negative and 3 = strong staining intensity.
Antibodies
To detect HectH9, we raised and affinity-purified a polyclonal antiserum against a protein corresponding to amino acids 3773-4374 of HectH9. Moreover we generated several monoclonal antibodies to HectH9 using standard techniques. The antigen used corresponds to amino acids 2530 to 2596 of HectH9. In addition, the following antibodies were used: α-cdk2 (M2; Santa Cruz), α-Myc (9E10; N-262, Santa Cruz), α-Miz1 (10E2, 3F3, 11F4) , rabbit or mouse α-HA (BAbCO), and mouse α-Vinculin (SIGMA).
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